Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Pharmacol Biochem Behav. 2011 Feb 4;98(3):349–355. doi: 10.1016/j.pbb.2011.02.001

Figure 3.

Figure 3

Effect of PDE4 inhibitors and citalopram on pleasure-seeking behavior in mice treated with PCPA in the FUST. Male mice received icv infusion of vehicle, citalopram, PDE4 inhibitor NCGC00167114, or PDE4 inhibitor NCGC00168459 for 14 days. Odor (water vs. urine), treatment (vehicle, citalopram, or PDE4 inhibitors), and interaction significantly affected time spent sniffing (a) (two-way repeated measures ANOVA, F-odor(1,34)=362.5, p<0.0001; F-treatment( 3,34)=9.074, p=0.0001; F-interaction(3,34)=15.84, p<0.0001). Citalopram had no significant effect (a) on time spent sniffing water (Bonferroni post-test, t=0.1187, p>0.05) or urine (Bonferroni post-test, t=0.2267, p>0.05). PDE4 inhibitor NCGC00167114 infusion (a) significantly increased time spent sniffing urine (Bonferroni post-test, t=2.937, p<0.05), but not water (Bonferroni post-test, t=0.2129, p>0.05). PDE4 inhibitor NCGC00168459 infusion (a) significantly increased time spent sniffing urine (Bonferroni post-test, t=6.135, p<0.001), but not water (Bonferroni post-test, t=0.09466, p>0.05). Treatment significantly influenced sniffing preference (b) (one-way ANOVA, F(3,37)=6.416, p=0.0015). Infusion of NCGC00168459, but not citalopram or NCGC00167114, significantly increased sniffing preference (b) (Bonferroni's Multiple Comparison Test; citalopram, t=1.013, p>0.05; NCGC00167114, t=1.742, p>0.05; NCGC00168459, t=2.782, p<0.05). Data are mean ± SD. *: p<0.05.